P27kip1 expression is associated with tumor response to preoperative chemoradiotherapy in rectal cancer

Annals of Surgical Oncology

Volumn 8, Issue 4, 2001, Pages 311-318

  Esposito, G ^a   Pucciarelli, S ^a   Alaggio, R ^a   Giacomelli, L ^a   Marchiori, E ^a   Iaderosa, G A ^b   Friso, M L ^b   Toppan, P ^b   Chieco Bianchi, L ^b   Lise, M ^c  

^a Servizio Citodiagnostica Mol Oncol   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Chemoradiotherapy; p27kip1; p53; Rectal cancer

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; FLUOROURACIL; FOLINIC ACID; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; PROTEIN P21;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BIOSYNTHESIS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROGNOSIS; RECTUM TUMOR; RETROSPECTIVE STUDY; TREATMENT OUTCOME; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG RESPONSE; FLOW CYTOMETRY; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN TISSUE; MICROSCOPY; MITOSIS INDEX; PROTEIN EXPRESSION; RADIATION DOSE; RECTUM ABDOMINOPERINEAL RESECTION; RECTUM CANCER; TUMOR DIFFERENTIATION; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CELL CYCLE PROTEINS; COMBINED MODALITY THERAPY; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LEUCOVORIN; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0034744271     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/aso.2001.8.4.311     Document Type: Article

References (64)

1. Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum
2. Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC)
3. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: Results from NSABP protocol R-01
4. The Stockholm II trial on preoperative short-term radiotherapy in operable rectal carcinoma: A prospective randomized trial
5. Improved survival with preoperative radiotherapy in resectable rectal cancer
6. Effective surgical adjuvant therapy for high-risk rectal carcinoma
7. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report
8. Final results of a randomized trial on the treatment of rectal cancer with preoperative radiotherapy alone or in combination with 5-fluorouracil, followed by radical surgery. Trial of the European Organization on Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group
9. Preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for rectal cancer
10. Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer
11. A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: A progress report of National Surgical Breast and Bowel Project Protocol R-03
12. High-dose preoperative radiation and the challenge of sphincter-preservation surgery for cancer of the distal 2 cm of the rectum
13. Preoperative chemoradiation downstages locally advanced ultrasound-staged rectal cancer
14. Role of pre-operative irradiation for anal preservation in cancer of the low rectum
15. Conservative surgery for low rectal carcinoma after high-dose radiation. Functional and oncologic results
16. Preoperative radiotherapy (RT) for rectal cancer: Predictive factors of tumor downstaging and residual tumor cell density (RTCD): Prognostic implications
17. Prognostic implications of downstaging following preoperative radiation therapy for operable T3-T4 rectal cancer
18. Apoptosis: Basic concepts and potential significance in human cancer
19. Apoptosis as a goal of cancer therapy
20. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
21. A histopathological assessment of the response of rectal adenocarcinoma to combination chemoradiotherapy: Relationship to apoptotic activity, p53 and bcl-2 expression
22. Alterations of p53 gene in primary gastric cancer tissues
23. Pancreatic adenocarcinomas frequently show p53 gene mutations
24. Association of p53 gene and protein alterations with metastases in colorectal cancer
25. Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis
26. Node negative breast carcinoma: Hyperprolactinemia and/or overexpression of p53 as an independent predictor of poor prognosis compared to newer and established prognosticators
27. Genetic studies and molecular markers of bladder cancer
28. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer
29. p53 and Rb1 protein expression: Are they prognostically useful in colorectal cancer?
30. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A Southwest Oncology Group study
31. p53 nuclear protein overexpression in colorectal cancer: A dominant predictor of survival in patients with advanced hepatic metastases
32. Participation of p53 protein in the cellular response to DNA damage
33. Wild-type p53 is a cell cycle checkpoint determinant following irradiation
34. Thymocyte apoptosis induced by p53-dependent and independent pathways
35. p53 is required for radiation-induced apoptosis in mouse thymocytes
36. Cloning of p27kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals
37. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21
38. A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells
39. Inhibitors of mammalian G1 cyclin-dependent kinases
40. Cancer cell cycles
41. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice
42. Accumulation of the cyclin-dependent kinase inhibitor p27/Kip1 and the timing of oligodendrocyte differentiation
43. Impact of the cyclin-dependent kinase inhibitor p27kip1 on resistance of tumor cells to anticancer agents
44. Promoting apoptosis: A novel activity associated with the cyclin-dependent kinase inhibitor p27
45. Colon and Rectum
46. Pathological features of rectal cancer after preoperative radiochemotherapy
47. Preoperative combined radiotherapy and chemotherapy for middle and lower rectal cancer: Preliminary results
48. Kip1 overexpression causes apoptotic death of mammalian cells
49. KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity
50. Kip1 induces drug resistance by preventing apoptosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells
51. Expression of p27 is associated with Bax expression and spontaneous apoptosis in oral and oropharyngeal carcinoma
52. Kip1 and apoptosis in tumor cells on the overall survival of patients with non-early stage gastric carcinoma
53. Kip1 and apoptosis in human breast cancer
54. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies
55. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27
56. Kip1 accumulation during the cell cycle
57. p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer
58. Apoptosis, proliferation, bax, bcl-2 and p53 status prior to and after preoperative radiochemotherapy for locally advanced rectal cancer
59. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
60. The p53 tumour suppressor gene
61. The apoptotic and transcriptional transactivation activities of p53 can be dissociated
62. Role of a mutant p53 protein in apoptosis: Characterization of a function independent of transcriptional trans-activation
63. Increased apoptosis induction by 121F mutant p53